

Raphaelle Seror

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5039992/raphaele-seror-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

9,170
citations

46
h-index

94
g-index

187
ext. papers

12,028
ext. citations

5.1
avg, IF

5.63
L-index

#	Paper	IF	Citations
166	Characteristics of Sjögren's syndrome associated with rheumatoid arthritis.. <i>RMD Open</i> , 2022 , 8,	5.9	0
165	Lifetime female hormonal exposure and risk of rheumatoid arthritis in postmenopausal women: results from the French E3N cohort.. <i>Joint Bone Spine</i> , 2022 , 105374	2.9	0
164	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	3
163	Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma.. <i>Joint Bone Spine</i> , 2022 , 89, 105390	2.9	0
162	Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses.. <i>RMD Open</i> , 2022 , 8,	5.9	1
161	SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. <i>Rheumatology</i> , 2021 , 60, 2946-2957	3.9	8
160	Dietary Recommendations of the French Society for Rheumatology for Patients with Chronic Inflammatory Rheumatic Diseases.. <i>Joint Bone Spine</i> , 2021 , 89, 105319	2.9	4
159	Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases.. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	5
158	Changes in Etanercept and Adalimumab Biosimilar Prescriptions for the Initial Treatment of Rheumatoid Arthritis in France: Data from the ART-SFR Registry. <i>Joint Bone Spine</i> , 2021 , 89, 105310	2.9	0
157	Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. <i>Lancet Rheumatology, The</i> , 2021 ,	14.2	11
156	Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 166	22.4	4
155	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1137-1146	2.4	49
154	Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice. <i>Clinical and Experimental Immunology</i> , 2021 , 205, 169-181	6.2	
153	PRACTICAL MANAGEMENT of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). <i>Joint Bone Spine</i> , 2021 , 88, 105174	2.9	
152	Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine. <i>Rheumatology International</i> , 2021 , 41, 1593-1600	3.6	2
151	Current and future therapies for primary Sjögren syndrome. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 475-486	8.1	10
150	Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS). <i>Joint Bone Spine</i> , 2021 , 88, 105162	2.9	2

149	Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2021 , 73, 631-640	9.5	13
148	Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS. <i>Rheumatology</i> , 2021 , 60, 675-681	3.9	4
147	Mediterranean Diet and Risk of Rheumatoid Arthritis: Findings From the French E3N-EPIC Cohort Study. <i>Arthritis and Rheumatology</i> , 2021 , 73, 69-77	9.5	11
146	Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy?. <i>Rheumatology</i> , 2021 , 60, 5413-5418	3.9	3
145	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021 , 38, 265-284	4.7	0
144	Female hormonal exposures and risk of rheumatoid arthritis in the French E3N-EPIC cohort study. <i>Rheumatology</i> , 2021 , 60, 4790-4800	3.9	2
143	Inflammation-targeted therapies and cancer. <i>Joint Bone Spine</i> , 2021 , 88, 105176	2.9	1
142	Clinically effective concentration and risk of hydroxychloroquine retinopathy in systemic lupus erythematosus: walking on a thin line. Comment on the article by Garg et al. <i>Arthritis Care and Research</i> , 2021 ,	4.7	
141	Denosumab in active Charcot neuro-osteoarthropathy of the foot. <i>Joint Bone Spine</i> , 2021 , 88, 105241	2.9	1
140	Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	2
139	Plasma cell gingivitis, an underestimated condition in patients with Sjögren's syndrome?. <i>Clinical and Experimental Rheumatology</i> , 2021 ,	2.2	
138	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. <i>RMD Open</i> , 2021 , 7, e001698	5.9	1
137	Plasma cell gingivitis, an underestimated condition in patients with Sjögren's syndrome?. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 225-225	2.2	
136	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 166-174	2.2	0
135	Concomitant fibromyalgia in primary Sjögren's syndrome in the French ASSESS cohort: comparison of the ACR 1990 and ACR 2016 criteria, FIRST questionnaire and physician's opinion.. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 133, 140-145	2.2	
134	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 133, 166-174	2.2	
133	Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort'. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	3
132	Chronic diarrhoea and risk of rheumatoid arthritis: findings from the French E3N-EPIC Cohort Study. <i>Rheumatology</i> , 2020 , 59, 3767-3775	3.9	9

131	Efficacy of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1257-1259	2.4	7
130	Seasonal effect on fatigue, pain and dryness in primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2020 , 22, 39	5.7	5
129	Small fiber neuropathy in Sjögren syndrome: Comparison with other small fiber neuropathies. <i>Muscle and Nerve</i> , 2020 , 61, 515-520	3.4	3
128	Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. <i>Rheumatology</i> , 2020 , 59, 3275-3283	3.9	2
127	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	24
126	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 3-18	2.4	139
125	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020 , 59, 2350-2359	3.9	24
124	Outcome Measures in Primary Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 134-149	4.7	2
123	Environment and Lifestyle: Their Influence on the Risk of RA. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	11
122	2020 French recommendations on the management of septic arthritis in an adult native joint. <i>Joint Bone Spine</i> , 2020 , 87, 538-547	2.9	15
121	Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. <i>Rheumatology</i> , 2020 , 59, 1347-1354	3.9	10
120	Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	22
119	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 85-94	2.2	1
118	Monocyte/Macrophage Abnormalities Specific to Rheumatoid Arthritis Are Linked to miR-155 and Are Differentially Modulated by Different TNF Inhibitors. <i>Journal of Immunology</i> , 2019 , 203, 1766-1775	5.3	20
117	Disease activity and patient reported outcome measures in Sjögren's - what are the best tools to evaluate?. <i>Rheumatology</i> , 2019 ,	3.9	4
116	Is miR200b-5p a new predictor of lymphoma or associated with lymphocytes infiltrate within salivary glands?. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e95	2.4	1
115	Passive smoking in childhood increases the risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, 1154-1162	3.9	24
114	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344

113	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019 , 5, e001064	5.9	24
112	Improving accuracy of self-reported diagnoses of rheumatoid arthritis in the French prospective E3N-EPIC cohort: a validation study. <i>BMJ Open</i> , 2019 , 9, e033536	3	5
111	Anti-RNP positivity in primary Sjögren's syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement. <i>RMD Open</i> , 2019 , 5, e001033	5.9	9
110	New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS. <i>Annals of the Rheumatic Diseases</i> , 2019 ,	2.4	11
109	Large granular lymphocyte expansions in primary Sjögren's syndrome: characteristics and outcomes. <i>RMD Open</i> , 2019 , 5, e001044	5.9	1
108	Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR). <i>Joint Bone Spine</i> , 2019 , 86 Suppl 1, eS2-eS103	2.9	5
107	Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. <i>Osteoporosis International</i> , 2019 , 30, 221-229	5.3	25
106	Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2019 , 18, 9-14	13.6	16
105	Usefulness of F-Labeled Fluorodeoxyglucose-Positron Emission Tomography for the Diagnosis of Lymphoma in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1147-1157	9.5	16
104	Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS). <i>British Journal of Haematology</i> , 2019 , 184, 472-475	4.5	7
103	Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. <i>Rheumatology</i> , 2018 , 57, 538-547	3.9	21
102	Iron Supplementation-Induced Phosphaturic Osteomalacia: FGF23 is the Culprit. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 540-542	6.3	18
101	Primary Sjögren's Syndrome Prevalence: What if Sjögren was Right After All? Comment on the Article by Maciel et al. <i>Arthritis Care and Research</i> , 2018 , 70, 951-953	4.7	4
100	Role of the IL-12/IL-35 balance in patients with Sjögren syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 258-268.e5	11.5	28
99	Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. <i>European Journal of Internal Medicine</i> , 2018 , 57, 96-104	3.9	20
98	Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1835-1836	2.4	5
97	Increase In IL-31 Serum Levels Is Associated With Reduced Structural Damage In Early Axial Spondyloarthritis. <i>Scientific Reports</i> , 2018 , 8, 7731	4.9	9
96	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 102-112	2.2	34

95	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Oencia in Rheumatoid Arthritis Registry. <i>Rheumatology</i> , 2017 , 56, 629-637	3.9	7
94	Cost-effectiveness of rituximab strategies in rheumatoid arthritis. <i>Lancet, The</i> , 2017 , 389, 365-366	4.0	3
93	2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 9-16	2.4	570
92	Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e3	2.4	1
91	Reply. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1342	9.5	3
90	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1042-1050	2.4	73
89	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017 , 16, 650-657	13.6	19
88	Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases. <i>Journal of Rheumatology</i> , 2017 , 44, 1011-1017	4.1	11
87	Guidelines for treatment of primary Sjögren's syndrome: a first useful stone but still much to do. <i>Rheumatology</i> , 2017 , 56, 1641-1642	3.9	4
86	F-FDG PET/CT of extensive rheumatoid nodulosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2333-2334	8.8	0
85	2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. <i>Arthritis and Rheumatology</i> , 2017 , 69, 35-45	9.5	517
84	Malignancy and the Risks of Biologic Therapies: Current Status. <i>Rheumatic Disease Clinics of North America</i> , 2017 , 43, 43-64	2.4	14
83	Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial. <i>Arthritis Care and Research</i> , 2017 , 69, 528-535	4.7	46
82	A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. <i>Rheumatology</i> , 2017 , 56, 362-370	3.9	24
81	Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care. <i>Journal of Clinical Epidemiology</i> , 2016 , 69, 235-44	5.7	2
80	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 1213-24	12.7	27
79	Reply. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1319-20	9.5	
78	Use of Biologics in Sjögren's Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2016 , 42, 407-17	2.4	18

77	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 382-9	2.4	144
76	IgG4-related disease associated with renal microaneurysms and polycythaemia. <i>Rheumatology</i> , 2016 , 55, 380-2	3.9	2
75	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 137-56	5.1	83
74	Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 780-3	2.4	29
73	Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1245-50	9.5	24
72	Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016 , 68, 977-85	9.5	106
71	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1945-1950	2.4	41
70	Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort. <i>Scientific Reports</i> , 2016 , 6, 18421	4.9	38
69	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 952-7	2.4	153
68	Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. <i>Lupus</i> , 2016 , 25, 1440-1447	2.6	15
67	Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. <i>Rheumatology</i> , 2015 , 54, 1699-708	3.9	44
66	Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , 2015 , 54, 2230-8	3.9	150
65	Genetic contribution of DKK-1 polymorphisms to RA structural severity and DKK-1 level of expression. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1480-1	2.4	9
64	Orbital Myositis and Primary Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2015 , 42, 1536-7	4.1	5
63	Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. <i>Rheumatology</i> , 2015 , 54, 2249-56	3.9	48
62	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 859-66	2.4	138
61	Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. <i>Rheumatology</i> , 2015 , 54, 424-32	3.9	63
60	Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 526-31	2.4	185

59	New biological therapies in Sjögren's syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015 , 29, 783-93	5.3	6
58	ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?. <i>RMD Open</i> , 2015 , 1, e000066	5.9	21
57	Association of Anti- <i>Porphyromonas gingivalis</i> Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1729-37	9.5	52
56	Reply: To PMID 25779552. <i>Arthritis and Rheumatology</i> , 2015 , 67, 3330	9.5	
55	CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2015 , 67, 3226-33	9.5	56
54	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?. <i>PLoS ONE</i> , 2015 , 10, e0133907	3.7	17
53	EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015 , 1, e000022	5.9	150
52	Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study. <i>Arthritis Research and Therapy</i> , 2015 , 17, 241	5.7	35
51	Severe and extreme idiopathic median nerve lesions at the wrist: new insights into electrodiagnostic patterns and review of the literature. <i>Muscle and Nerve</i> , 2015 , 51, 201-6	3.4	3
50	Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort. <i>PLoS ONE</i> , 2015 , 10, e0134974	3.7	20
49	Outcome measures for primary Sjögren's syndrome: a comprehensive review. <i>Journal of Autoimmunity</i> , 2014 , 51, 51-6	15.5	55
48	Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sjögren's syndrome. <i>Scandinavian Journal of Immunology</i> , 2014 , 79, 37-42	3.4	24
47	Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , 2014 , 371, 1771-80	59.2	573
46	Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2074-81	2.4	139
45	Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 681-8	5.3	11
44	OP0217 Defining Disease Activity Sates and Minimal Clinically Important Improvement (MCI) with the EULAR Primary Sjögren's Syndrome Disease Activity Index (ESSDAI). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 144.2-145	2.4	9
43	OP0218 Elevated Serum BAFF is Associated with an Increased Risk of Developing A New Systemic Complication: Data from the Prospective ASSESS Cohort. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 145.1-145	2.4	
42	THU0264 In Early Rheumatoid Arthritis (Espoir Cohort), Serum CCL19 Level is Associated with Disease Activity, Autoantibody Secretion and 3-Year Radiographic Progression: Data from the Espoir Cohort. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 274.2-274	2.4	

41	Reporting of results from network meta-analyses: methodological systematic review. <i>BMJ, The</i> , 2014 , 348, g1741	5.9	102
40	Update of strategies to translate evidence from cochrane musculoskeletal group systematic reviews for use by various audiences. <i>Journal of Rheumatology</i> , 2014 , 41, 206-15	4.1	15
39	Epidemiology of primary Sjögren's syndrome in a French multiracial/multiethnic area. <i>Arthritis Care and Research</i> , 2014 , 66, 454-63	4.7	69
38	Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses. <i>Journal of Rheumatology</i> , 2014 , 41, 194-205	4.1	90
37	Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 249-58	27.4	176
36	Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 42, 507-14	5.3	75
35	Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 476-8	2.4	73
34	L'obésité comme facteur de risque des atteintes sèvées des nerfs médians aux poignets. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013 , 80, 587-593	0.1	
33	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. <i>Arthritis and Rheumatism</i> , 2013 , 65, 270-81		488
32	Prevalence of obesity and obesity as a risk factor in patients with severe median nerve lesion at the wrist. <i>Joint Bone Spine</i> , 2013 , 80, 632-7	2.9	7
31	European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients. <i>Arthritis Care and Research</i> , 2013 , 65, 1358-64	4.7	48
30	Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review. <i>BMJ, The</i> , 2013 , 347, f3675	5.9	70
29	Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2013 , 65, 3218-27		40
28	Severe deafness associated with Crohn's disease and spondylarthropathy: successful treatment with anti-TNF. <i>Rheumatology</i> , 2013 , 52, 1145-7	3.9	6
27	Pattern of demyelination occurring during anti-TNF therapy: a French national survey. <i>Rheumatology</i> , 2013 , 52, 868-74	3.9	95
26	Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort. <i>PLoS ONE</i> , 2013 , 8, e59868	3.7	110
25	Outcome measures for primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2012 , 39, 97-102	15.5	40
24	Hand workload, computer use and risk of severe median nerve lesions at the wrist. <i>Rheumatology</i> , 2012 , 51, 362-7	3.9	8

23	Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. <i>Rheumatology</i> , 2012 , 51, 460-7	3.9	105
22	EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 968-72	2.4	264
21	Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. <i>Arthritis Care and Research</i> , 2011 , 63, 277-85	4.7	71
20	The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. <i>Medicine (United States)</i> , 2011 , 90, 19-27	1.8	505
19	Excessive FMS-like tyrosine kinase3-ligand heralds lymphoma in primary sjgren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, A59-A59	2.4	
18	Cervical syphilitic spondylodiscitis associated with neurosyphilis. <i>Rheumatology</i> , 2011 , 50, 1723-5	3.9	2
17	Looking into the Future—the EULAR Disease Activity Scores: Toward a Consensual Evaluation of Primary Sjogren's Syndrome 2011 , 443-454		
16	Measure of function in rheumatoid arthritis: individualised or classical scales?. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 97-101	2.4	37
15	Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 2125-30	2.4	34
14	EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1103-9	2.4	542
13	Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. <i>Blood</i> , 2010 , 116, 4070-6	2.2	105
12	Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies. <i>Joint Bone Spine</i> , 2010 , 77, 604-7	2.9	9
11	Reporting of corticosteroid use in systemic disease trials: evidence from a systematic review of the potential impact on treatment effect. <i>Arthritis Care and Research</i> , 2010 , 62, 1002-8	4.7	5
10	Accurate detection of changes in disease activity in primary Sjgren's syndrome by the European League Against Rheumatism Sjgren's Syndrome Disease Activity Index. <i>Arthritis Care and Research</i> , 2010 , 62, 551-8	4.7	60
9	Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. <i>Arthritis and Rheumatism</i> , 2010 , 62, 616-26		360
8	High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 564-7	2.4	150
7	Individualising the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) function subscale: incorporating patient priorities for improvement to measure functional impairment in hip or knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 494-9	2.4	11
6	Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2747-54		71

5	Progressive osseous heteroplasia: a rare case of late onset. <i>Rheumatology</i> , 2007 , 46, 716-7	3.9	9
4	Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 351-7	2.4	216
3	Plasma exchange for rheumatoid arthritis. <i>Transfusion and Apheresis Science</i> , 2007 , 36, 195-9	2.4	8
2	Meralgia paresthetica: clinical and electrophysiological diagnosis in 120 cases. <i>Muscle and Nerve</i> , 2006 , 33, 650-4	3.4	77
1	Central nervous system involvement in Wegener granulomatosis. <i>Medicine (United States)</i> , 2006 , 85, 53-65	6.8	148